Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Overview
Authors
Affiliations
Journal Journal of Clinical Oncology.The development of immune checkpoint inhibitors has revolutionized the management of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The landmark KEYNOTE-048 clinical trial established the programmed death-1 inhibitor pembrolizumab with and without chemotherapy as a new standard first-line treatment for patients with platinum-sensitive R/M HNSCC. Nonetheless, clinical decision making can be challenging when considering the significant morbidity associated with rapidly progressive disease in high-risk locations, patient fitness, and programmed death-ligand 1 expression. Both planned and unplanned subgroup analyses from KEYNOTE-048 provide valuable insights into how therapy for untreated R/M HNSCC may be optimized for individual patients. Given differences in the toxicity profile of pembrolizumab alone versus in combination with chemotherapy, prioritizing patient preference is paramount in this palliative treatment setting. Here, the case of a patient presenting with de novo metastatic HNSCC is discussed to highlight the practical application of KEYNOTE-048 data in clinical practice.
He D, Yang Z, Zhang T, Luo Y, Peng L, Yan J Mol Ther Nucleic Acids. 2025; 36(1):102413.
PMID: 40027882 PMC: 11869859. DOI: 10.1016/j.omtn.2024.102413.
Wang M, Zhao B, Huang A, Song M, Wang J, Liu P J Cancer. 2025; 16(3):996-1007.
PMID: 39781346 PMC: 11705048. DOI: 10.7150/jca.105254.
Liu L, Liu Q Sci Rep. 2024; 14(1):9914.
PMID: 38688945 PMC: 11061135. DOI: 10.1038/s41598-024-60516-6.
Deng H, Wei Z, Du J, Shen Z, Zhou C Eur J Med Res. 2023; 28(1):548.
PMID: 38017579 PMC: 10683111. DOI: 10.1186/s40001-023-01521-9.
p63 orchestrates serine and one carbon metabolism enzymes expression in head and neck cancer.
Cappello A, Tosetti G, Smirnov A, Ganini C, Yang X, Shi Y Biol Direct. 2023; 18(1):73.
PMID: 37946250 PMC: 10636826. DOI: 10.1186/s13062-023-00426-1.